文献速递胸部肿瘤放疗

T分期与治疗前标准化摄取值预测早期非小细胞肺癌5次大分割立体定向消融放疗后的肿瘤复发

T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer.
PubMed 文献 · Adv Radiat Oncol · 2022-05-21

本研究纳入90例T1-2非小细胞肺癌患者,接受50 Gy或60 Gy分5次立体定向消融放疗(SABR)。全队列2年总生存率75.8%、无进展生存率59.3%,50 Gy与60 Gy组生存及失败率无差异。仅T分期和治疗前PET标准化摄取值(SUV)预测局部、区域及远处失败。

要点

  • 5次SABR的2年局部失败率为7.8%,全队列2年总生存率75.8%、无进展生存率59.3%。
  • 总剂量50 Gy与60 Gy在2年和5年生存率及失败率上无差异。
  • T分期和治疗前PET标准化摄取值是局部、区域及远处失败的预测因素。

核心结论

  • 5次SABR提供了极好的照射野内控制。
  • T2期和高氟脱氧葡萄糖摄取肿瘤的失败率增加,提示可能需要辅助治疗,正在随机3期试验中评估。

研究设计与样本

  • 90例T1-2非小细胞肺癌患者接受50 Gy或60 Gy分5次SABR治疗。
  • 采用累积发生率模型分析局部、区域或远处失败,以死亡为竞争风险,并用Cox比例风险分析控制患者变量。

主要发现

  • 90例患者中,53例T1肿瘤患者中24例、37例T2肿瘤患者中19例接受50 Gy SABR,其余47例接受60 Gy。
  • 全队列2年总生存率和无进展生存率分别为75.8%和59.3%。
  • 总SABR剂量(50 Gy vs 60 Gy)未影响2年和5年生存率及失败率。
  • 治疗2年内,7.8%的患者出现局部失败。
  • 在所有评估的患者和肿瘤特征中,仅T分期和治疗前PET标准化摄取值在单因素和多因素分析中预测治疗后2年和5年的局部、区域和远处失败。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Five-fraction stereotactic ablative radiotherapy (SABR) regimens are frequently used to treat centrally located early-stage non-small cell lung cancer or disease in the proximity of the chest wall as a means of optimizing tumor control and reducing treatment toxicity. However, increasing these SABR regimens to 5 fractions may reduce tumor control outcomes. We sought to identify the clinical parameters predictive of treatment failures with these 5-fraction courses. METHODS: Ninety patients with T1-2 non-small cell lung cancer were treated with 50 or 60 Gy in 5 fractions. Failure over time was modeled using cumulative incidences of local, regional, or distant failure, with death as a competing risk. Cox proportional hazards analysis for incidences of failure was performed to control for patient variables. RESULTS: Of 90 patients, 24 of 53 patients with T1 tumors and 19 of 37 patients with T2 tumors received 50 Gy SABR, and the other 47 patients received 60 Gy. Two-year overall survival and progression-free survival for the whole cohort were 75.8% and 59.3%, respectively. Total SABR dose (50 vs 60 Gy) did not influence survival nor failure rates at 2 and 5 years. Within 2 years of treatment, 7.8% of all patients developed local failure. For all patient and tumor characteristics evaluated, only T stage and pretreatment positron emission tomography standardized uptake values served as predictors of local, regional, and distant failure at 2 and 5 years posttreatment on univariate and multivariable analysis. CONCLUSIONS: Five-fraction SABR provides excellent in-field control. T2 and high fluorodeoxyglucose uptake tumors have increased failure rates, suggesting the potential need for adjuvant therapies, which are being assessed in randomized phase 3 trials.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hsu EJ, Mendel JT, Ward KA, et al. T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer. Adv Radiat Oncol. 2022. PMID: 36148376. doi:10.1016/j.adro.2022.100995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。